Trials / Recruiting
RecruitingNCT05245058
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of SPH5030 tablets in subjects with HER2-positive advanced solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPH5030 tablets | SPH5030 tablets orally once or twice daily. |
Timeline
- Start date
- 2022-01-21
- Primary completion
- 2025-12-21
- Completion
- 2025-12-21
- First posted
- 2022-02-17
- Last updated
- 2025-08-17
Locations
17 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05245058. Inclusion in this directory is not an endorsement.